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also computed and reported as confidence intervals in the 
outcome reports. 
Relevant literature was inserted and made readily available 
to the user. 
Figure 1 shows a screen shot of the web tool:  
 
Conclusions: This work proved that it is possible to provide 
clinicians with a support tool that enables them to use in 
their clinical practice results coming from scientific 
literature, thus helping translation of clinical studies into 
daily routine. 
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Purpose/Objective: Globally, prostate cancer is responsible 
for around 250000 deaths annually. Radiotherapy is an 
effective definitive treatment and, for more aggressive 
disease, is commonly preceded by neo-adjuvant androgen 
deprivation therapy (ADT). It has been demonstrated that 
dose escalated radiotherapy improves biochemical free 
survival but not overall survival. Further dose escalation is 
limited by OAR tolerances. Giving a further focal boost to the 
dominant intra-prostatic lesion (DIPL) appears to be feasible. 
The DIPL is effectively identified using multi-parametric (MP) 
MR imaging, however, ADT results in a reduction in prostate 
and tumour volume and also a loss of contrast on T2w MR 
images, making lesions less conspicuous. The DIPL is 
therefore conventionally identified on pre-hormone imaging 
but it is known that response to therapy is variable and 
directing a DIPL boost to disease that is resistant to ADT may 
be most likely to improve clinical outcome. The aim of this 
work was to compare pre and post treatment imaging to 
evaluate the feasibility of using post treatment MP-MRI to 
locate the DIPL. 
Materials and Methods: Six patients with prostate cancer 
stage T2b or greater were recruited. All underwent local pre 
ADT DWI. Patients were imaged post ADT at 1.5 T (Achieva, 
Philips Medical Systems, Best, The Netherlands) using the 
cardiac coil. The MR examination included high resolution 
T2w images, DCE-MRI and diffusion-weighted imaging (DWI). 
ADC and DCE-MRI parameter maps were calculated on a 
voxel-by-voxel basis for the whole prostate. 
Results: Four patients had a clear DIPL pre ADT. This 
remained largely unchanged in appearance in three cases 
post ADT, as shown in the example case in the top row of 
figure 1, where arrows indicate the high flow (left, Fp in 
ml/ml tissue/min overlayed on T2w imaging), low ADC (right, 
overlayed on T2w imaging) regions matching those reported 
as tumour on pre-treatment imaging. In one case the pre ADT 
DIPL in the right peripheral zone was hard to identify post 
ADT on T2w imaging (black arrow bottom row, figure 1). 
However a further lesion in the left anterior gland (white 
arrow), which was equivocal in appearance pre-treatment, 




Conclusions: This study has shown that for this cohort post 
ADT MP-MR is effective at identifying a DIPL for focal boost 
therapy. In one case the area which would be targeted for 
dose escalation changed pre and post ADT. The use of post 
ADT Fp and ADC therefore appears to have potential for 
identifying areas of disease which are resistant to ADT. It is 
known from animal studies that these areas are likely to be 
radio-resistant and benefit most from dose escalation. Using 
pre-ADT MP-MR may therefore carry the risk of failing to 
correctly identify the area of prostate requiring dose 
escalation. This study forms part of a larger piece of work 
aiming to validate these findings and assess changes in 
tumour MP-MR characteristics during radiotherapy after neo-
adjuvant ADT. 
 
 
 
 
